Intriguingly, the impact of STM2457 on AML development and the suppressive effects of FTO inhibitor FB23-2 on AML cell proliferation highlight the complex interplay between methylation and demethylation processes (Huang et al., 2019; Yankova et al., 2021). The gene discussed is FTO; the disease is acute myeloid leukemia.